McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. DOI: 10.1016/j.schres.2005.07.014. PubMed PMID: 16137860.
Barnes TRE, Paton C, Cavanagh M-R, Hancock E, Taylor DM. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull. 2007;33(6):1397-403. DOI: 10.1093/schbul/sbm038. PubMed PMID: 17483101; PubMed Central PMCID: PMC2779874.
Shahid M, Walker GB, Zorn SH, Wong EHF. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73. DOI: 10.1177/0269881107082944. PubMed PMID: 18308814.
Gladigau EL, Fazio TN, Hannam JP, Dawson LM, Jones SG. Increased cardiovascular risk in patients with severe mental illness. Intern Med J. 2014;44(1):65-9. DOI: 10.1111/imj.12319. PubMed PMID: 24383746.
Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007;64(10):1123-31. DOI: 10.1001/archpsyc.64.10.1123. PubMed PMID: 17909124.
Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. Bmc Psychiatrybmc Psychiatry. 2013;13:246. DOI: 10.1186/1471-244X-13-246. PubMed PMID: 24094241; PubMed Central PMCID: PMC3853885.